同德化工(002360.SZ):自然人龔尚鍾對同德新材料增資4400萬元
格隆匯3月15日丨同德化工(002360.SZ)公佈,公司的全資子公司同德資產,對外投資設立的控股孫公司同德通,同德通持有浙江同德新材料科技有限公司(以下簡稱“目標公司”)100%的股權。自然人龔尚鍾以現金方式出資人民幣4400萬元,對目標公司進行增資,在本次增資完成後,目標公司的註冊資本變為人民幣5500萬元,其中同德通佔目標公司出資額的20%股權,龔尚鍾佔目標公司出資額的80%股權;目標公司的經營範圍:主要是以電子特氣貿易(電子特氣主要應用於高階AMOLED顯示屏產業、10奈米以下之最高階半導體制程等)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.